- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Wells Score.
Displaying page 1 of 1.
EudraCT Number: 2006-004290-97 | Sponsor Protocol Number: ACCILTRA1 | Start Date*: 2008-12-19 |
Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy | ||
Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle... | ||
Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005194-30 | Sponsor Protocol Number: P-AD337-021 | Start Date*: 2006-06-12 |
Sponsor Name:Arakis Ltd. | ||
Full Title: A multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study to investigate the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in fem... | ||
Medical condition: Fibromyalgia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001411-25 | Sponsor Protocol Number: XPORT-COV-1001 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection | |||||||||||||
Medical condition: Severe COVID-19 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004325-25 | Sponsor Protocol Number: MS325-19 | Start Date*: 2007-01-04 |
Sponsor Name:Administration management, Ludwig-Maximilians-University of Munich | ||
Full Title: Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist® | ||
Medical condition: Patients with low or moderate clinical probability for pulmonary embolism and positive or negative CTA for pulmonary embolism after CT and sonographic examination for deep venous thrombosis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003957-14 | Sponsor Protocol Number: KCP-330-023 | Start Date*: 2017-03-14 | |||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myelom... | |||||||||||||
Medical condition: Relapsed or refractory multiple myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GR (Completed) AT (Completed) CZ (Completed) BE (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003594-14 | Sponsor Protocol Number: KCP-330-020 | Start Date*: 2018-07-03 | |||||||||||
Sponsor Name:Karyopharm Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) | |||||||||||||
Medical condition: Dedifferentiated Liposarcoma (DDLS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) ES (Completed) SE (Completed) BE (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006007-15 | Sponsor Protocol Number: JAKAR | Start Date*: 2022-09-01 | |||||||||||
Sponsor Name:Leiden University Medical Center (LUMC) | |||||||||||||
Full Title: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis | |||||||||||||
Medical condition: patients with ACPA-positieve active RA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001733-13 | Sponsor Protocol Number: CP007 | Start Date*: 2012-10-04 | |||||||||||
Sponsor Name:Circassia Limited | |||||||||||||
Full Title: A Double Blind, Randomised, Placebo Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects | |||||||||||||
Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) BE (Completed) CZ (Completed) DE (Completed) HU (Completed) SK (Completed) LT (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003809-60 | Sponsor Protocol Number: XPORT-MF-035 | Start Date*: 2021-07-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||||||||||||
Full Title: A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis | |||||||||||||||||||||||||||||||||
Medical condition: Myelofibrosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) PL (Temporarily Halted) GR (Completed) IT (Ongoing) ES (Temporarily Halted) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002625-29 | Sponsor Protocol Number: GWSP19066 | Start Date*: 2020-01-14 | ||||||||||||||||
Sponsor Name:GW Pharma Limited | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis | ||||||||||||||||||
Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003271-18 | Sponsor Protocol Number: GWSP20105 | Start Date*: 2021-06-07 | ||||||||||||||||
Sponsor Name:GW Pharma Limited | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis | ||||||||||||||||||
Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Ongoing) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003544-37 | Sponsor Protocol Number: ABUHB/01/0816/1 | Start Date*: 2016-11-30 | ||||||||||||||||||||||||||
Sponsor Name:Aneurin Bevan University Health Board | ||||||||||||||||||||||||||||
Full Title: Perineural Local Anaesthetic Catheter aftEr Major lowEr limb amputatioN Trial (PLACEMENT) | ||||||||||||||||||||||||||||
Medical condition: Analgesia for lower limb amputation for peripheral vascular disease (PVD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002854-11 | Sponsor Protocol Number: OOC-ACM-302 | Start Date*: 2016-04-18 | |||||||||||
Sponsor Name:Chiasma, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPS... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) RO (Completed) LT (Completed) DE (Completed) NL (Prematurely Ended) ES (Completed) AT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004669-15 | Sponsor Protocol Number: CP007A | Start Date*: 2014-06-16 | |||||||||||
Sponsor Name:Circassia Limited | |||||||||||||
Full Title: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment | |||||||||||||
Medical condition: Treatment of cat allergen induced rhinoconjunctivitis in patients with clinically relevant symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002623-14 | Sponsor Protocol Number: GWSP18023 | Start Date*: 2020-03-17 | ||||||||||||||||
Sponsor Name:GW Pharma Ltd | ||||||||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis | ||||||||||||||||||
Medical condition: Symptomatic relief of spasticity in Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) PL (Completed) GB (GB - no longer in EU/EEA) RO (Ongoing) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.